There are currently 7 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are .
PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
NCT06923111
Recruiting
This post-authorisation safety and efficacy study (PRECISE PASS) evaluates the use of Xromi® (hydroxycarbamide 100 mg/mL oral solution) in children aged 9 months to under 2 years with sickle cell disease (SCD). The objective is to assess the safety profile and clinical effectiveness of Xromi® under routine clinical conditions. The study includes a prospective cohort of Xromi®-treated patients and a matched retrospective comparator cohort of untreated patients. Participants will be followed for... Read More
Gender:
ALL
Ages:
Between 9 months and 23 months
Trial Updated:
08/01/2025
Locations: Basildon University Hospital, Basildon, Essex +4 locations
Conditions: Sickle Cell Disease
Register for Updates
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268
Recruiting
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the par... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/14/2025
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +160 locations
Conditions: Sickle Cell Disease
Register for Updates
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B). Double-blind period has two parts, 50% (adult only) until the interim analysis (a proof-concept part... Read More
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
07/04/2025
Locations: Bioresearch Partners- Site Number : 8400005, Hialeah, Florida +2 locations
Conditions: Sickle Cell Disease
Register for Updates
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712
Recruiting
This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat. Eligible participants who enter the study will start a 96-week treatment period. At the end of the 96 weeks, participants will have an end of study visit that occurs 4 weeks later. The participants will receive etavopiv... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
06/16/2025
Locations: The Hospital for Sick Children, Toronto, Ontario +14 locations
Conditions: Sickle Cell Disease
Register for Updates
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649
Recruiting
This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
10/16/2024
Locations: Atrium Health Levine Children's Hospital, Charlotte, North Carolina +6 locations
Conditions: Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
Register for Updates
The Living With a Long-Term Condition Study
NCT06072287
Recruiting
Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs). Being able to measure whether psychological distress is related to living with a LTC would allow researchers and clinicians to provide interventions specifically tailored to the challenges of living with a LTC and therefore provide the most appropriate support for these patients. Such a measure would also be useful in research to identify the presence... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: King's College London, London, Not set
Conditions: Asthma, Atrial Fibrillation, Cancer, Cerebrovascular Disorders, Stroke, CKD, Copd, Fibromyalgia, Pain, Heart Diseases, Heart Disease Chronic, Dementia, Diabetes, Epilepsy, Heart Failure, High Blood Pressure, Hypertension, Hiv, AIDS, IBD, IBS, Liver Diseases, Long COVID, Lupus Erythematosus, Multiple Sclerosis, Obesity, Osteoarthritis, Arthritis, Rheumatoid Arthritis, Osteoporosis, Parkinson Disease, Sickle Cell Disease, Hepatitis, Endometriosis, PCOS, Neurological Disorder, POTS - Postural Orthostatic Tachycardia Syndrome, MND (Motor Neurone DIsease), Cystic Fibrosis, Migraine, Spondylitis, Celiac Disease, Hidradenitis Suppurativa, Eczema, ME/CFS
Register for Updates
RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease
NCT05392894
Recruiting
The purpose of this clinical trial is to evaluate the clinical and cost effectiveness of Haploidentical Stem Cell Transplantation (SCT) for adults with severe sickle cell disease (SCD), who have failed other therapies or are intolerant of existing therapies or require chronic transfusions to prevent on-going complications of SCD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2023
Locations: King's College Hospital, London, Not set
Conditions: Sickle Cell Disease
Register for Updates